ResearcherWestern UniversityNo recent work listed
Nicole Mittmann
Matched on ORCID iD 0000-0002-3759-2316; OpenAlex author ID A5102784127. Sources: OpenAlex.
Their work
- Papers
- 5 (first author 0, last author 1)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 13
2015: 1 paper · 2016: 2 papers · 2017: none · 2018: none · 2019: none · 2020: 1 paper · 2021: none · 2022: 1 paper
Papers 5
- Real-World Cost-Effectiveness of First-Line Gemcitabine Plus Nab-Paclitaxel vs FOLFIRINOX in Patients With Advanced Pancreatic Cancer. Co-author DOI 10.1093/jncics/pkac047↗
- Real-world outcomes of FOLFIRINOX vs gemcitabine and nab-paclitaxel in advanced pancreatic cancer: A population-based propensity score-weighted analysis. Co-author DOI 10.1002/cam4.2705↗
- The association of adjuvant therapy with survival at the population level following pancreatic adenocarcinoma resection. Co-author DOI 10.1016/j.hpb.2015.12.005↗
- Predictors of adjuvant treatment for pancreatic adenocarcinoma at the population level. Co-author DOI 10.3747/co.23.3205↗
- A population-based study of the epidemiology of pancreatic cancer: a brief report. Last author DOI 10.3747/co.22.2653↗
Closest collaborators
The 13 strongest of 13 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Natalie G. Coburn · 4 shared papers, 2015–2020 · strength 0.23
- Paper Real-world outcomes of FOLFIRINOX vs gemcitabine and nab-paclitaxel in advanced pancreatic cancer: A population-based p… DOI 10.1002/cam4.2705↗
- Paper The association of adjuvant therapy with survival at the population level following pancreatic adenocarcinoma resection. DOI 10.1016/j.hpb.2015.12.005↗
- Paper Predictors of adjuvant treatment for pancreatic adenocarcinoma at the population level. DOI 10.3747/co.23.3205↗
- Wei Fang Dai · 2 shared papers, 2020–2022 · strength 0.22
- Paper Real-World Cost-Effectiveness of First-Line Gemcitabine Plus Nab-Paclitaxel vs FOLFIRINOX in Patients With Advanced Pan… DOI 10.1093/jncics/pkac047↗
- Paper Real-world outcomes of FOLFIRINOX vs gemcitabine and nab-paclitaxel in advanced pancreatic cancer: A population-based p… DOI 10.1002/cam4.2705↗
- Kelvin Chan · 2 shared papers, 2020–2022 · strength 0.22
- Paper Real-World Cost-Effectiveness of First-Line Gemcitabine Plus Nab-Paclitaxel vs FOLFIRINOX in Patients With Advanced Pan… DOI 10.1093/jncics/pkac047↗
- Paper Real-world outcomes of FOLFIRINOX vs gemcitabine and nab-paclitaxel in advanced pancreatic cancer: A population-based p… DOI 10.1002/cam4.2705↗
- R.S. Raju · 3 shared papers, 2015–2016 · strength 0.15
- Paper The association of adjuvant therapy with survival at the population level following pancreatic adenocarcinoma resection. DOI 10.1016/j.hpb.2015.12.005↗
- Paper Predictors of adjuvant treatment for pancreatic adenocarcinoma at the population level. DOI 10.3747/co.23.3205↗
- Paper A population-based study of the epidemiology of pancreatic cancer: a brief report. DOI 10.3747/co.22.2653↗
- Vanessa Sarah Arciero · 1 shared paper, 2022 · strength 0.13
- Ambica Parmar · 1 shared paper, 2022 · strength 0.13
- Michael Jonathon Raphael · 1 shared paper, 2022 · strength 0.13
- Daniel Jonathan Kagedan · 2 shared papers, 2016 · strength 0.10
- Matthew E. B. Dixon · 2 shared papers, 2016 · strength 0.10
- James Biagi · 1 shared paper, 2020 · strength 0.09
- Erin Diane Kennedy · 1 shared paper, 2020 · strength 0.09
- Qing Li · 1 shared paper, 2016 · strength 0.05
- Jeffrey S. Hoch · 1 shared paper, 2015 · strength 0.04
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.